TY - JOUR
T1 - Challenges in clinical metaproteomics highlighted by the analysis of acute leukemia patients with gut colonization by multidrug-resistant enterobacteriaceae
AU - Rechenberger, Julia
AU - Samaras, Patroklos
AU - Jarzab, Anna
AU - Behr, Juergen
AU - Frejno, Martin
AU - Djukovic, Ana
AU - Sanz, Jaime
AU - González-Barberá, Eva M.
AU - Salavert, Miguel
AU - López-Hontangas, Jose Luis
AU - Xavier, Karina B.
AU - Debrauwer, Laurent
AU - Rolain, Jean Marc
AU - Sanz, Miguel
AU - Garcia-Garcera, Marc
AU - Wilhelm, Mathias
AU - Ubeda, Carles
AU - Kuster, Bernhard
N1 - Publisher Copyright:
© 2019 by the authors.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - The microbiome has a strong impact on human health and disease and is, therefore, increasingly studied in a clinical context. Metaproteomics is also attracting considerable attention, and such data can be efficiently generated today owing to improvements in mass spectrometry-based proteomics. As we will discuss in this study, there are still major challenges notably in data analysis that need to be overcome. Here, we analyzed 212 fecal samples from 56 hospitalized acute leukemia patients with multidrug-resistant Enterobactericeae (MRE) gut colonization using metagenomics and metaproteomics. This is one of the largest clinical metaproteomic studies to date, and the first metaproteomic study addressing the gut microbiome in MRE colonized acute leukemia patients. Based on this substantial data set, we discuss major current limitations in clinical metaproteomic data analysis to provide guidance to researchers in the field. Notably, the results show that public metagenome databases are incomplete and that sample-specific metagenomes improve results. Furthermore, biological variation is tremendous which challenges clinical study designs and argues that longitudinal measurements of individual patients are a valuable future addition to the analysis of patient cohorts.
AB - The microbiome has a strong impact on human health and disease and is, therefore, increasingly studied in a clinical context. Metaproteomics is also attracting considerable attention, and such data can be efficiently generated today owing to improvements in mass spectrometry-based proteomics. As we will discuss in this study, there are still major challenges notably in data analysis that need to be overcome. Here, we analyzed 212 fecal samples from 56 hospitalized acute leukemia patients with multidrug-resistant Enterobactericeae (MRE) gut colonization using metagenomics and metaproteomics. This is one of the largest clinical metaproteomic studies to date, and the first metaproteomic study addressing the gut microbiome in MRE colonized acute leukemia patients. Based on this substantial data set, we discuss major current limitations in clinical metaproteomic data analysis to provide guidance to researchers in the field. Notably, the results show that public metagenome databases are incomplete and that sample-specific metagenomes improve results. Furthermore, biological variation is tremendous which challenges clinical study designs and argues that longitudinal measurements of individual patients are a valuable future addition to the analysis of patient cohorts.
KW - Clinical proteomics
KW - Data analysis
KW - Human gut microbiome
KW - Mass spectrometry
KW - Metaproteome
KW - Multi-omics
KW - Multidrug-resistant Enterobacteriaceae
KW - Proteomics
UR - https://www.scopus.com/pages/publications/85065404091
U2 - 10.3390/proteomes7010002
DO - 10.3390/proteomes7010002
M3 - Article
AN - SCOPUS:85065404091
SN - 2227-7382
VL - 7
JO - Proteomes
JF - Proteomes
IS - 1
M1 - 2
ER -